GloMY was a randomised pilot trial of Myfortic for the treatment of primary proteinuric glomerulonephritis, which closed on Tuesday 21st August, 2012.
Chief Investigator: Prof Lorraine Harper
Trial Sponsor: University Hospital Birmingham NHS Foundation Trust
West of Scotland REC Ref. No.: 10/S0703/27
EUDRACT No: 2009- 016003-26
GloMY was a national, multi-centre, randomised controlled open-label pilot trial of Myfortic plus short course steroids versus standard care in patients with proteinuric primary focal segmental glomerulosclerosis (FSGS) and IgA nephropathy (IgAN).
To determine the feasibility of running a full-scale phase III randomised trial of Myfortic plus short course steroids versus standard care in patients with FSGS or IgAN, and to obtain preliminary comparative data on the efficacy of Myfortic plus short course steroids in inducing sustained response in patients with FSGS or IgAN.
GloMY Sample Size:
Recruitment of 100 patients with FSGS and IgAN over 24 months was planned (50 to Myfortic with short course steroids and 50 to standard care), with a minimum number of 40 patients with each disease type. GloMY closed to recruitment on 21st Aug 2012 with 12 patients randomised and 26 centres fully approved.